tbuckley/cabot-search huggingface dataset:
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Authors: Jaya Sangodkar, Abbey Perl, Rita Tohme, Janna Kiselar, David B. Kastrinsky, Nilesh Zaware, Sudeh Izadmehr, Sahar Mazhar, Danica D. Wiredja, Caitlin M. O’Connor, Divya Hoon, Neil S. Dhawan, Daniela Schlatzer, Shen Yao, Daniel Leonard, Alain C. Borczuk, Giridharan Gokulrangan, Lifu Wang, Elena Svenson, Caroline C. Farrington, Eric Yuan, Rita A. Avelar, Agnes Stachnik, Blake Smith, Vickram Gidwani, Heather M. Giannini, Daniel McQuaid, Kimberly McClinch, Zhizhi Wang, Alice C. Levine, Rosalie C. Sears, Edward Y. Chen, Qiaonan Duan, Manish Datt, Shozeb Haider, Avi Ma’ayan, Analisa DiFeo, Neelesh Sharma, Matthew D. Galsky, David L. Brautigan, Yiannis A. Ioannou, Wenqing Xu, Mark R. Chance, Michael Ohlmeyer, Goutham Narla
Journal: Journal of Clinical Investigation (2017)

Targeted cancer therapies, which act on specific cancer-associated molecular targets, are predominantly inhibitors of oncogenic kinases. While these drugs have achieved some clinical success, the inactivation of kinase signaling via stimulation of endogenous phosphatases has received minimal attention as an alternative targeted approach. Here, we have demonstrated that activation of the tumor suppressor protein phosphatase 2A (PP2A), a negative regulator of multiple oncogenic signaling proteins, is a promising therapeutic approach for the treatment of cancers. Our group previously developed a series of orally bioavailable small molecule activators of PP2A, termed SMAPs. We now report that SMAP treatment inhibited the growth of KRAS-mutant lung cancers in mouse xenografts and transgenic models. Mechanistically, we found that SMAPs act by binding to the PP2A Aα scaffold subunit to drive conformational changes in PP2A. These results show that PP2A can be activated in cancer cells to inhibit proliferation. Our strategy of reactivating endogenous PP2A may be applicable to the treatment of other diseases and represents an advancement toward the development of small molecule activators of tumor suppressor proteins.
Healthcare personnel intestinal colonization with multidrug-resistant organisms
Authors: B.K. Decker, A.F. Lau, J.P. Dekker, C.D. Spalding, N. Sinaii, S. Conlan, D.K. Henderson, J.A. Segre, K.M. Frank, T.N. Palmore
Journal: Clinical Microbiology and Infection (2017)
Treatment cascade of hepatitis B and C in general, migrant and Roma populations
Authors: G. Touloumi, A. Karakosta, S. Kaskafetou, I. Petraki, O. Anagnostou, M. Gavana, G. Papatheodoridis, A. Kalpourtzi, T. Mimikou, T. Antypas, M. Kantzanou, G. Rachiotis, A. Vantarakis, G. Chlouverakis, P. Voulgari, Y. Alamanos, G. Trypsianis, V. Sypsa
Journal: Journal of Hepatology (2017)
Is R2 resection a valuable salvage treatment for colorectal liver metastases?
Authors: Jose Luis Beristain-Hernandez, Marc Antoine Allard, Katsunori Imai, Carlos Castro Benitez, Eric Vibert, Antonio Sa Cunha, Daniel Cherqui, Pasquale F. Innominato, Mohamed Bouchahda, Francis Levi, Jean F. Morere, Denis Castaing, Henri Bismuth, Rene Adam
Journal: Journal of Clinical Oncology (2015)

e14602 Background: Patients with multiple colorectal liver metastases (CRLM) are always considered in an intention to resect all metastases (R0/R1resection). However technical constraints make that sometimes no more than a R2 (incomplete) resection can be achieved, The results of these procedures of debulking surgery in CRLM have never been evaluated in a period of increasing efficacy of chemotherapy Methods: The study consists in a retrospective analysis of all the consecutive patients with CRLM treated by a first R2 liver resection, from 1994 to 2012 at a single center Characteristics of patients (age, sex), of metastases (date of diagnosis, number and size, tumor markers), of chemotherapy received preoperatively (type, number of cycles, response according to Recist criteria) and of liver surgery (date, cause for R2) were correlated to the patient outcome. Volumes for all liver metastases were calculated: in CT scan and on pathological report. A percentage of tumor left was calculated based on the substraction of both for all metastases. Results: Among a global cohort of 1170 patients resected of CRLM, 172 had resections identified as R2 (100%). Of these, 93 (54%) were first stage hepatectomies that succesfully completed a two-stage hepatectomy, while the remaining 79 patients had true R2 resections (45.9%) with no extra-hepatic disease and formed the study population. R2 resection was due to failed two-stage hepatectomy in 46 (58.2%) patients, failure to accomplish a maximal one-stage resection in 11 (13.9%); an ill located tumor in 8 (10%) or other causes in 14 (17%). The mean percentage of tumor left in situwas 63.8% of all the tumor load with 24% of patients having < 30% residual tumor. A partial response to preoperative chemotherapy was observed in 55.6% with stabilisation in 29% and progression in 15%. For all patients with R2 resection, 5-year survival rate was 28% and the median survival was 39 months. For patients with a combination of response to chemotherapy and < 30% of tumor left in place, the 5-year survival rate was 54% and the median survival was 95 months. Conclusions: R2 resection may allow selected patients to achieve long-term survival provided that chemotherapy is efficient and remnant tumoral load is low.
Bioengineering of an Intraabdominal Endocrine Pancreas
Authors: David A Baidal, Camillo Ricordi, Dora M Berman, Ana Alvarez, Nathalia Padilla, Gaetano Ciancio, Elina Linetsky, Antonello Pileggi, Rodolfo Alejandro
Journal: New England Journal of Medicine (2017)

This letter describes islet transplantation onto the omentum with the use of a degradable scaffold in a patient with a 25-year history of type 1 diabetes mellitus. The patient remained insulin-independent for more than 1 year.
Early Detection of Myelodysplastic Syndromes: Maximizing the Utility of Automated Hematology
Authors: Yamina Lilliana Carattini, Terrence Bradley, Fernando Vargas, Justin M Watts, Jennifer R Chapman, German Campuzano-Zuluaga, Francisco Vega, Deukwoo Kwon, Ronan T Swords
Journal: Blood (2016)
Erratum: Neurotrophins use the Erk5 pathway to mediate a retrograde survival response (Nature Neuroscience (2001) 4 (981-988))
Authors: Fiona L. Watson, Heather M. Heerssen, Anita Bhattacharyya, Laura Klesse, Michael Z. Lin, Rosalind A. Segal
Journal: Nature Neuroscience (2002)
Therapy with direct acting antivirals in patients with hepatitis C virus related lymphoproliferative disorders and mixed cryogloglobulinemia
Authors: L. Venezia, G. Troshina, A. Tucci, P. Ponzo, M. Sacco, A. Smedile, M. Rizzetto, G.M. Saracco, A. Ciancio
Journal: Journal of Hepatology (2017)
A comparative study of blood-based <i>KRAS</i> mutation analysis in circulating tumor cells versus circulating plasma DNA to predict primary tumor mutations in lung cancer.
Authors: Eric Kian Saik Lim, Maxim B Freidin, Dasha V Freydina, Dimple Chudasama, Maria Leung, Sanjay Popat, David Gonzalez de Castro, Alexandra Rice, Vladimir Anikin, Angeles Montero Fernandez, Andrew G Nicholson
Journal: Journal of Clinical Oncology (2014)

7563 Background: Biopsy of the primary tumour for predictive testing is not always convenient nor possible and may incur both delays and complications. In a move towards blood based predictive testing for personalised medicine, we sought to determine the test performance of circulating tumour cell (CTC) versus circulating tumour DNA (ctDNA) as a surrogate of the underlying tumour mutations using KRAS (a common mutation) as a prototype. Methods: KRAS mutation status in primary tumours were analysed using cobas4800 (Roche) allele-specific PCR. From 9ml of blood, ScreenCell MB devices were used to capture CTCs and the DNA was extracted from CTC and matched plasma using QIAamp DNA kits (QIAGEN). KRAS mutation detection was undertaken using custom-designed high-resolution melting assay and confirmed by pyrosequencing using therascreen kit (QIAGEN). Results: From January 2012 to 2013 the peripheral blood of 92 patients who underwent surgery for lung cancer at The Royal Brompton Hospital were analysed for mutations in codons 12/13 of KRAS gene. The total number of patients with KRAS mutations in FFPE tumour tissue was 18 (19.6%), the ctDNA was 17 (20%) and CTC DNA was 47 (58.8%). In total 9 primary tumours identified as “wild-type” in FFPE tissue appeared mutant in ctDNA. After 7 FFPE samples were re-tested by pyrosequencing, 6 previously undetected KRAS mutations were revealed. After re-testing FFPE tissue, the final concordance between primary tumours and ctDNA was 92% and concordance between CTC DNA was 52%. The sensitivity and specificity for blood based predictive KRAS testing was 81% (95% CI 58%-96%) and 97% (87%-100%) for ctDNA and 86% (61%-98%) and 38% (23%-56%) for CTC DNA. Conclusions: Blood based mutation testing is feasible and FFPE tumour biopsies cannot always be considered to be the “reference” as KRAS mutations not initially detected in the tumour were detected in the blood. ctDNA may be more reflective of the global tumour burden and is more closely indicative of underlying tumour mutation compared to CTC DNA due to tumour heterogeneity.
NONMYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT) FROM HLA-MATCHED RELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES: CLINICAL RESULTS OF A TBI-BASED CONDITIONING REGIMEN
Authors: Bm Sandmaier, Dg Maloney, T Gooley, U Hegenbart, J Shizuru, F Sahebi, T Chauncey, E Agura, B Bruno, P Mcsweeney, S Forman, K Blume, D Niederwieser, R Strob
Journal: Blood (2001)
Transient elastography correlates with liver fibrosis and markers of portal hypertension in PSC: laennec score-based analysis of explanted livers
Authors: M. Krawczyk, J. Ligocka, M. Ligocki, M. Zawadzki, M. Milkiewicz, G. Szparecki, B. Górnicka, M. Krawczyk, F. Lammert, P. Milkiewicz
Journal: Journal of Hepatology (2017)
Prediction for the incidence of hepatocellular carcinoma in patients with chronic hepatitis B after administration of nucleos(t)side analog
Authors: H. Takahashi, C. Okuse, N. Yamada, T. Niinuma, E. Yamamoto, M. Kai, H. Wakasugi, N. Akutsu, H. Yotsuyanagi, M. Suzuki, F. Itoh, H. Suzuki
Journal: Journal of Hepatology (2017)
Improved Values for Acquired Von Willebrand Syndrome and Better Clinical Outcome in Patients with Heartmate III Compared to Heartmate II
Authors: Ulrich Geisen, Kerstin Brehm, Georg Trummer, Friedhelm Beyersdorf, Michael Berchtold-Herz, Claudia Heilmann, Johannes Schelling, Axel Schlagenhauf, Barbara Zieger
Journal: Blood (2016)
Myocardial Fibrosis in Duchenne and Becker Muscular Dystrophy
Authors: Robert C. Bahler
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Metabolism of N’-nitrosonornicotine by precision-cut rodent lung slices.
Authors: Bettina Lassnack, Elmar Richter, Anthony R. Tricker
Journal: Cancer Research (2004)

3198  Precision-cut tissue slices in dynamic organ culture retain their cellular architecture and metabolic activity for several hours, suggesting that organ slices are a suitable in vitro model for studying tissue metabolism of xenobiotics. N’-Nitrosonornicotine (NNN) is reported to induce tumors of the lung in A/J mice, and esophagus and nasal mucosa in the F344 rat. The major routes of NNN metabolism are α-hydroxylation to yield either 2’-hydroxyNNN or 5’-hydroxyNNN, pyridine-N-oxidation, and concerted denitrosation and oxidation to norcotinine. Minor pathways of metabolism include β-hydroxylation to yield either 3’-hydroxyNNN or 4’-hydroxyNNN. Of all the potential routes of NNN metabolism, 2’-hydroxylation is thought to be the major activation pathway yielding target tissue DNA adducts, and the ratio of 2’-hydroxylation to 5’-hydroxylation is often considered to indicate the extent of NNN activation. 2’-Hydroxylation of 0.004 to 1.2 μM [5-3H]NNN (27 Ci/mmol) in precision-cut A/J mouse lung tissue slices (6 h at 37 °C) proceeded on average 8.6±1.4 fold faster (Km: 3.09±5.19 μmol, Vmax: 3178±4104 fmol/min/mg protein) than 2’-hydroxylation of [5-3H]NNN in precision-cut F344 rat lung tissue slices under identical experimental conditions (Km: 0.08±0.07 μmol, Vmax: 60±12 fmol/min/mg protein). In the same concentration range the difference for 5’-hydroxylation was less pronounced, 4.5±0.8 fold higher turnover in mouse lung slices (Km: 1.42±1.63 μmol, Vmax: 792±567 fmol/min/mg protein) compared to rat lung slices (Km: 0.14±0.11 μmol, Vmax: 61±13 fmol/min/mg protein). The ratio of 2’-hydroxylation to 5’-hydroxylation was significantly higher in A/J mouse lung (2.3±0.1) compared to in F344 rat lung (1.2±0.1) over the whole concentration range. These results, which support increased metabolic activation of NNN in the A/J mouse lung compared to in the F344 rat lung, are also consistent with the reported target organ specificity of NNN in both rodent species.
Abstract 17875: The Potential Impact of a New Sodium Reduction Technology on Dietary Intakes & Health Outcomes: NHANES Modeling
Authors: Victor L Fulgoni, Lisa A Spence, Priscilla Samuel
Journal: Circulation (2013)

Average sodium intake in America is over 3000 mg/day, greatly exceeding recommended intakes of 2300 mg/day and for certain at risk groups of 1500 mg/day. Using data from NHANES 2007-2010 with exclusions for unreliable data and pregnant or lactating females, we modeled the potential impact on sodium intake with the use of a sodium reduction technology: SODA LO TM  Salt Microspheres (Tate & Lyle, Hoffman Estates, IL).   Based on potential usage levels provided by Tate & Lyle food developers, 953 foods were targeted for reduction. Suggested sodium reductions ranged from 20-30% depending on the particular food. We modeled sodium usual intakes by assuming four levels of market penetration (10, 20, 50, and 100%). SAS 9.2 and SUDAAN 11 are used for all calculations, the National Cancer Institute method (covariates used included recall day sequence, DRI age groups, and weekend intake indicator) was used for usual intake determination with and without sodium reduction scenarios, and NHANES survey weights were used in all calculations Analyses were assessed by five age groups (2+, 2-18, 19+,19-50, 51+ years of age), for gender combined and males and females separately. At the estimated 100% market penetration a sodium reduction of 274, 281, 271, 290, and 244 mg/day for those 2+, 2-18, 19+,19-50, 51+ years of age was estimated, respectively. The reductions were greater (p
Pulmonary function tests (PFT) results in a phase 1 (Ph1) oncology patient (pt) population.
Authors: Priscila Hermont Goncalves, Ayman O. Soubani, Lance K. Heilbrun, Daryn W. Smith, Juan Villegas, Patricia LoRusso
Journal: Journal of Clinical Oncology (2015)

e17759 Background: In a prior Ph1 oncology trial at our institution, 9 out of 14 patients (pts) consented were screen failures due to Grade (G) ≥ 2 PFT results, based on the Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 3. This current study was done to obtain the distribution of the PFT parameters in a typical Ph1 oncology pt population. Methods: Pts underwent a PFT according to the American Thoracic Society (ATS) consensus. Eligibility: no history (hx) of lung radiation or symptomatic lung metastases. Pts had to be non-smokers or had a smoking hx less than 10 pack-year and quit smoking > 1 year. Study objectives were to determine: 1) diffusing capacity of the lungs for carbon monoxide (DLCO) (as % of predicted) corrected for hemoglobin (DLCOc); 2) the percentage of pts who met defined PFT eligibility for Ph1 trial participation, i.e. the number of pts having DLCOc ≥ 75-90% of predicted (CTCAE v 3 Grade 1 (G1)) or normal. A 1-stage study design assumed a reference DLCO standard deviation of 14.21% (of predicted) from the 14 prior Ph1 study oncology pts. We sought to estimate the mean DLCO to within 4 units of its true value, with 95% confidence (N = 52 pts). Results: Enrollment stopped at 48 pts. Median age was 58 years (range 28 – 85); 44 pts were Caucasian; 29 pts were female; median number of prior non-Ph1 treatments was 3; and 42 pts were never smokers. The mean DLCOc was 93% of predicted (95% confidence interval [CI]: 87 – 99%). G ≥ 2 (CTCAE v3) DLCOc was noted in 11 (23%) pts. If the CTCAE v4 were applied, 5 pts would be classified as G1, 1 as G3, and 42 as normal. Using the ATS criteria for reduced DLCOc, 5, 3 and 40 pts would be classified as mild, moderate and normal, respectively. Conclusions: Ours is the first prospective study of PFT in Ph1 oncology pts. Among a group of oncology pts pre-selected for better pulmonary function and considered for Ph1 trials at our institution, almost a quarter would be screen failures based on CTCAE v 3 for DLCOc. CTCAE v4 appear to be better criteria to facilitate accrual to oncology Ph1 trials and are more congruent to the ATS criteria, which are used by pulmonologists to grade PFT parameters. Using our study eligibility criteria should help select patients more likely to have DLCOc ≤ grade 1 by CTCAE v4. Clinical trial information: NCT00914147.
Brain metastases (BMs) from metastatic renal cell carcinoma (RCC) in patients (pts) treated with molecularly targeted agents (MTAs).
Authors: Haris Ali, Jingsheng Yan, Yull Edwin Arriaga, Xian-Jin Xie, James Brugarolas
Journal: Journal of Clinical Oncology (2012)

e15066 Background: Historically, the frequency of BMs from RCC is ~11%. Recent reports have suggested an improvement in the incidence of BMs with tyrosine kinase inhibitors (TKIs). What is not known is the impact of MTAs on the prevalence of BMs in metastatic RCC. Methods: We conducted a retrospective review of all pts with metastatic RCC treated with MTAs at a tertiary care center, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, from 2006–2010. Statistical analyses were performed using the Cox proportional hazards model and the Kaplan-Meier method. Results: Fifty nine pts met inclusion criteria. 8 more pts presented with BMs and were not included in the incidence and survival analyses. Median age was 64.6 yrs. Per MSKCC criteria, 3 pts were in favorable (5%), 41 in intermediate (70%), and 15 in poor (25%) prognostic groups. Sites of metastases at presentation included lungs (65%), lymph nodes (40%), bones (30%), and liver (25.4%). Mean follow up time was 16 months, and at last follow up 24 pts were alive. The incidence of BMs was 11.9% (7/59) and the prevalence was 22% (15/67). Median overall survival was 1.97 yrs (95% CI, 1.04-3.89). Median survival for pts who developed BMs vs. without BMs was 1.21 yrs vs. 1.98 yrs (p=0.17). In multivariable analyses, only lack of nephrectomy was associated with increased risk of BMs, HR=9.819 (95 CI, 1.65-58.38; p=0.012). Conclusions: In our study, the incidence of BMs in RCC pts treated with MTAs was similar to what has been historically reported. In contrast, the prevalence of BMs was much higher at 22%. This is the first study to report the prevalence of BMs in patients with metastatic RCC treated with MTAs. As in other tumor types, the life-time risk of BMs appears to increase with the availability of highly-active MTAs.
High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
Authors: J Pan, J F Yang, B P Deng, X J Zhao, X Zhang, Y H Lin, Y N Wu, Z L Deng, Y L Zhang, S H Liu, T Wu, P H Lu, D P Lu, A H Chang, C R Tong
Journal: Leukemia (2017)
Predictors for successful downstaging in patients with BCLC intermediate stage hepatocellular carcinoma
Authors: A. Broekhoven, B. Takkenberg, D. Sprengers, S. Ramsoekh, K. van Erpecum, S. van Meer, H. Verspaget, M. Burgmans, S. Osanto, A. Baranski, M. Fiocco, M. Coenraad
Journal: Journal of Hepatology (2017)
Effects of melatonin in hepatopulmonary syndrome induced biliar duct ligation in rats
Authors: N.P. Marroni, J.R. Colares, A.D. Bosco, E.G. Schemitt, R.M. Hartmann, F. Licks, M.D.C. Soares, A.S. Dias
Journal: Journal of Hepatology (2017)
Abstract 160: Pim-1 Preserves Cardiac Stem Cell Proliferation with Age
Authors: Michael McGregor, Shabana Din, Natalie Gude, Mark A Sussman
Journal: Circulation Research (2012)

Rationale Cardiac stem cells (CSC) regulate cardiomyogenesis and support regenerative processes in the heart, but aging adversely affects stem cell repair capacity. Aging is a primary cause of impaired cardiac function characterized by accumulation of senescent cells. CSC senescence is associated with permanent growth arrest that decreases survival signaling and cellular replacement, inevitably diminishing the capacity of the heart to maintain tissue homeostasis. Therefore, promoting CSC growth may improve cardiac performance with age. Pim-1 kinase exhibits protective and proliferative effects in the myocardium but the role of Pim-1 in cardiac aging has not been thoroughly studied. Objective Demonstrate that Pim-1 promotes stem cell growth in the aged myocardium correlating with increased expression of centromere protein A (CENP-A), a kinetochore-associated protein known to support cell proliferation in numerous species and cell types. Methods &amp; Results CENP-A expression levels were evaluated from murine myocardial tissue samples ranging in age from 11 days post coitum to 4 months of age with analysis by immunoblot as well as quantitative PCR. CENP-A expression was colocalized with c-kit as a marker of CSC by immunohistochemical labeling, revealing a decline in CENP-A expression over the time course of postnatal myocardial maturation. The impact of Pim-1 upon CENP-A level was assessed by comparative analysis of non-transgenic mice versus genetically modified transgenic mouse lines expressing either Pim-1 (wild type) or a dominant negative functionally dead Pim-1 mutant. Pim-1 overexpression increases persistence of CENP-A in CSCs with age, as well as the prevalence of cycling CSCs as marked by phosph-H3 expression, while the functionally dead mutant accelerates CENP-A diminution and decreases CSC proliferation. Conclusion CENP-A decline in c-kit positive cells with age provides intriguing evidence of a potential mechanism for the diminished capacity of CSCs to maintain tissue homeostasis. Pim-1 mitigates CENP-A diminution, demonstrating the promising potential of Pim-1 to promote cardiac growth and repair with age.
Embrio-Foetal Erythroid Precursors in the Coelomic Fluid From Humans.
Authors: Maria Concetta Renda, Antonino Giambona, Emanuela Fecarotta, Filippo Leto, George Makrydimas, Disma Renda, Gianfranca Damiani, Maria Cristina Jakil, Francesco Picciotto, Mauro Valtieri, Tiziana Piazza, Aurelio Maggio
Journal: Blood (2009)
The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in &gt;1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis
Authors: M. Manns, E.J. Gane, B.E. Willems, S.K. Roberts, S. Flamm, M. Bourliére, T. Asselah, L. Alric, R.H. Hyland, L.M. Stamm, K.C. Huang, D.M. Brainard, M. Khalili, G.R. Foster, S.C. Gordon, K.R. Reddy, S. Zeuzem, I.M. Jacobson, C.L. Cooper, A.J. Thompson, K. Kowdley, E. Lawitz
Journal: Journal of Hepatology (2017)